DL-Homocysteine

Research use only, not for human use.

DL-Homocysteine is a potential marker for tumor cell growth. increased plasma homocysteine is a risk factor for coronary heart disease and carcinogenesis.

DL-Homocysteine is a potential marker for tumor cell growth. increased plasma homocysteine is a risk factor for coronary heart disease and carcinogenesis.

DL-Homocysteine (0.1-0.5 mM) significantly enhances kynurenic acid (KYNA) production in rat cortical slices, and diministes the production of at 3.0, 5.0, and 10.0 mM, with the estimated IC50 of 6.4 (5.5-7.5) mM. DL-Homocysteine dose-dependently inhibits kynurenine aminotransferases I (KATI) activity at concentrations ≥0.2 mM, with an IC50 of 0.566 (0.442-0.724) mM, and the activity of KAT II with IC50 value of 8.046 (5.804-11.154) mM.

DL-Homocysteine (1.3 mmol/kg, i.p.) increases KYNA content (pmol/g tissue) from 8.47 ± 1.57 to 13.04 ± 2.86 and 11.4 ± 1.72 in cortex, and from 4.11 ± 1.54 to 10.02 ± 3.08 in rat hippocampus.

2-Amino-4-mercaptobutyric acid

Proteasome/Ubiquitin

Endogenous Metabolite

Human Endogenous Metabolite

——

——

454-29-5

135.19

C4H9NO2S

>98% (HPLC)

DMSO:10 mM;Water:Soluble

NC(CCS)C(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years